Final FDA Guidance Gives Sponsors More Flexibility In Using Latest Industry Standards For Biologics Submissions

FDA’s biologics center has issued final guidance to sponsors on acceptable practices for using industry standards in developing regulatory submissions for new biologics and drugs.